慢性粒细胞白血病患者临床治疗剖析.docVIP

慢性粒细胞白血病患者临床治疗剖析 　　[摘要] 目的 探讨临床治疗慢性粒细胞白血病的有效方法。方法 方便选取该院2011年6月―2017年6月收治的80例慢性粒细胞白血病患者，随机分成两组，对照组40例患者接受口服羟基尿治疗，实验组40例接受伊马替尼联合干扰素-α治疗，对比两组患者的治疗总有效率，得出结论。结果 实验组40例患者治疗总有效率为95.00%，对照组40例患者治疗总有效率为70.00%。对照组患者的总体治疗有效率明显低于实验组，数据对比差异有统计学意义（P0.05）。实验组患者发生2例患者出现不良反应，不良反应的发生率为5.00%，对照组患者10例患者出现不良反应，不良发音的发生率为25.00%，对照组患者的治疗的不良反应发生率明显高于实验组，?稻荻员炔钜煊型臣蒲б庖澹?P 0.05）。结论 伊马替尼联合干扰素-α能够提高患者的治疗有效率，减少患者在治疗过程中不良反应的发生率，值得临床推广。 　　[关键词] 慢性粒细胞白血病；羟基尿；伊马替尼；干扰素-α 　　[中图分类号] R5 [文献标识码] A [文章编号] 1674-0742（2017）09（b）-0013-03 　　[Abstract] Objective This paper tries to investigate the effective method of clinical treatment for chronic myelomonocytic leukemia. Methods 80 cases of chronic myeloid leukemia patients in this hospital from June 2011 to June 2017 were convenient selection randomly divided into two groups， with 40 patients in each group， the control group received oral hydroxyurea treatment， and the experimental group received imatinib combined with interferon-α treatment， the total efficiency of the treatment were compared between two groups. Results The total effective rate was 95.00% in the experimental group and the control group was 70.00%. The total effective rate of the control group was significantly lower than that of the experimental group， the difference was statistically significant （P0.05）. Two cases of adverse reactions occurred in the experimental group， the incidence rate of adverse reaction was 5.00%， ten cases of adverse reactions occurred in the control group， with the incidence rate of 25.00%， the adverse reactions in the control group was significantly higher than the experimental group， with statistically significant difference （P0.05）. Conclusion Imatinib combined with interferon alpha can improve the efficiency of the treatment of patients， reduce the incidence of adverse reactions in the treatment process， and is worthy of clinical promotion. 　　[Key words] Chronic myelomonocytic leukemia； Hydroxyurea； Imatinib； Interferon alpha 　　慢性粒细胞白血病是（chronic myelocytic